Viracta Therapeutics (VIRX)
(Delayed Data from NSDQ)
$0.58 USD
-0.14 (-19.22%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $0.61 +0.03 (5.17%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Viracta (VIRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.50 | $11.00 | $4.00 | 802.78% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Viracta comes to $6.50. The forecasts range from a low of $4.00 to a high of $11.00. The average price target represents an increase of 802.78% from the last closing price of $0.72.
Analyst Price Targets (4 )
Broker Rating
Viracta currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 25% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/12/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
8/15/2023 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.25 |
# of Recs in ABR | 4 |
Average Target Price | $6.50 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -0.35 |